GlobalData has reviewed the growth of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. IO trials were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center using an ‘immuno-oncology’ filter based on drugs tagging.

Immuno-oncology therapies are separated into four broad segments:

  • Adoptive cellular therapy, which includes chimeric antigen receptor T-cell immunotherapy (CAR-T), cytotoxic T lymphocyte immunotherapy (CTL), natural killer cell immunotherapy (NKT), regulatory T cells (Treg), and tumor-infiltrating lymphocyte immunotherapy (TIL).
  • Immune checkpoint modulators.
  • Immune system modulators, which include various cancer vaccines.
  • Immunomodulatory enzyme inhibitors.

The highest growth was attributed to immune checkpoint modulators, where the number of trials increased at a much higher rate than the other IO segments, concurrent with the surge in investigations into PD-1 targets (see Figure 1).

Figure 1: global IO clinical trials, N, by segment

Source: GlobalData. © GlobalData

Related Reports

GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, Report Code: GDHC009PFR.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For more insight and data, visit the GlobalData Report Store – Drug Development Technology is part of GlobalData Plc.